Isoray

Isoray, Inc. is a medical technology company based in Richland, Washington, founded in 2004. The company specializes in developing, manufacturing, and commercializing isotope-based medical products for cancer treatment, particularly focusing on Cesium-131 (Cs-131) brachytherapy seeds. These seeds are used in internal radiation therapy to treat various cancers, with a primary emphasis on prostate cancer. Isoray's flagship product received U.S. FDA approval in 2010 and is designed to deliver targeted, minimally invasive radiation therapy directly to tumor sites. In 2023, Isoray merged with Viewpoint Molecular Targeting, Inc. to form Perspective Therapeutics, Inc. This merger combines Isoray's expertise in brachytherapy with Viewpoint's targeted alpha-particle therapies, aiming to enhance precision cancer treatments. Isoray's products are utilized by healthcare providers and cancer treatment centers, serving oncologists who specialize in various cancer types. The company is committed to advancing treatment paradigms through innovative solutions and strategic partnerships.

• Employees 66
• Founded 1998
• Annual Revenue $1434000
• Total Funding $21528750